{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for alpha root_Display\ Name in Display Name (approximate match)
Status:
Possibly Marketed Outside US
Source:
Antiseptic Solution by Grupo Salypro de Mexico, S.A. de C.V.
(2021)
Source URL:
First approved in 2016
Source:
All Day Skin Relief with Colloidal Oats by Lantern Enterprises Ltd.
Source URL:
Class:
MIXTURE
Status:
US Approved Rx
(2003)
First approved in 1987
Source:
PROLASTIN-C by GRIFOLS THERAPEUTICS LLC
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02957266: Phase 3 Interventional Unknown status Cervical Cancer
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00374855: Phase 2 Interventional Completed Mild Hypertension
(2006)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00001296: Phase 3 Interventional Completed Melanoma
(1992)
Source URL:
Class:
PROTEIN
Status:
Designated
Source:
FDA ORPHAN DRUG:773920
Source URL:
Class:
PROTEIN
Status:
Designated
Source:
EU-Orphan Drug:EU/3/03/138
Source URL:
Class:
PROTEIN
